Scholarlink

<p>Biliary tract cancers (BTC) are aggressive and fatal. Early recognition of symptoms and proper diagnostic work up allow for precise histopathological and molecular classification as well as accurate evaluation of the extent of disease. Surgery is the only potentially curative therapy in localized stages; however, disease recurrence is common and adjuvant chemotherapy appears to improve survival. Upfront systemic chemotherapy with immunotherapy is the treatment of choice in unresectable locally-advanced and metastatic disease. Inroads made in understanding its molecular biology has enabled new therapeutic targets to be identified with current indications and encouraging results that could further improve BTC patients’ survival and quality of life.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

SEOM-GEMCAD-TTD clinical guidelines for biliary tract cancer (2025)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月30日

查看全文
  • Teresa Macarulla,
  • Jorge Adeva,
  • Maria Teresa Cano Osuna,
  • Ana Ruiz Casado,
  • Ana María Jiménez Gordo,
  • Angela Lamarca,
  • Ana María López Muñoz,
  • Roberto Antonio Pazo Cid,
  • Tamara Saurí,
  • Javier Gallego Plazas

摘要

Biliary tract cancers (BTC) are aggressive and fatal. Early recognition of symptoms and proper diagnostic work up allow for precise histopathological and molecular classification as well as accurate evaluation of the extent of disease. Surgery is the only potentially curative therapy in localized stages; however, disease recurrence is common and adjuvant chemotherapy appears to improve survival. Upfront systemic chemotherapy with immunotherapy is the treatment of choice in unresectable locally-advanced and metastatic disease. Inroads made in understanding its molecular biology has enabled new therapeutic targets to be identified with current indications and encouraging results that could further improve BTC patients’ survival and quality of life.